Cencora, Inc. · NYSE:COR
Cencora — AmerisourceBergen — Q3 FY2018 Earnings Presentation
13 slides from Cencora's earnings presentation, Aug 2, 2018
Slide 1: Q3 FY2018 Financial Results
Q3 FY2018 Financial Results August 2, 2018
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements Certain of the statements contained in this presentation are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Words such as “expect,” “likely,” “ou
Slide 3: AmerisourceBergen is creating healthier futures
AmerisourceBergen is creating healthier futures • Shaping healthcare delivery through knowledge, reach and partnership • Providing industry leading services and solutions that improve product access, increase supply chain efficiency and enhance patient care 3
Slide 4: Highly Differentiated & Strongly Positioned for Growth
Highly Differentiated & Strongly Positioned for Growth Customer Base Innovative Services & • Key anchor customers Solutions • Fast growing • Customer-focused offerings serving • U.S. Pharmaceutical focus manufacturers and provider customers Leadership in Specialty Successful Financial Distribution &
Slide 5: Q3 FY2018 Financial Results: Overview
Q3 FY2018 Financial Results: Overview ▪ AmerisourceBergen businesses are executing and creating value for its partners - Continued revenue and EPS growth - Strong performance in our core pharmaceutical distribution business continues - PharMEDium’s Memphis facility is open and expects to commence co
Slide 6: Q3 FY2018 Financial Results
Q3 FY2018 Financial Results Adjusted GAAP (Non-GAAP)1 Revenue $43.1B $43.1B % Change (Year-over-Year) 11% 11% Gross Profit $1.2B $1.2B % Change 12% 11% Operating Expenses $822M $697M % Change (10)% 19% Operating Income $389M $474M % Change 128% 1% Interest Expense, Net $47M $47M % Change 32% 36% Tax
Slide 7: Pharmaceutical Distribution Services Segment
Q3 FY2018 Financial Results: Pharmaceutical Distribution Services Segment Q3 FY2018 Q3 FY2017 Revenue $41.6B $37.3B Operating Income $393M $380M Percentages of Revenue Gross Profit 2.07% 2.03% Operating Expenses 1.13% 1.01% Operating Income 0.94% 1.02% Core distribution businesses continuing to ex
Slide 8: Other Businesses – Global Commercialization Services & Animal Health
Q3 FY2018 Financial Results: Other Businesses – Global Commercialization Services & Animal Health Q3 FY2018 Q3 FY2017 Revenue $1.6B $1.5B Operating Income $82M $91M Percentages of Revenue Gross Profit 19.40% 20.26% Operating Expenses 14.25% 14.03% Operating Income 5.15% 6.22% World Courier – anoth
Slide 9: FY2018 Financial Guidance
FY2018 Financial Guidance1 Expectations on an Adjusted (Non-GAAP) Basis* Revenue Growth 8% to 11% Diluted Earnings Per Share $6.45 to $6.65 Operating Expense Growth 8% to 10% Operating Income Growth Flat Effective Tax Rate ~22% Free Cash Flow $1.35B to $1.6B Capital Expenditures ~$325M Working Assum
Slide 10: Appendix
Appendix N) AmerisourceBergen:
Slide 11: Appendix
Appendix Note: For more information related to non-GAAP financial measures, refer to the section titled “Supplemental Information Regarding Non-GAAP Financial Measures” in the exhibit to the Company’s most recent Current Report on Form 8-K furnished under Item 2.02. 11
Slide 12: Appendix: Update
Appendix UPDATE Note: For more information related to non-GAAP financial measures, refer to the section titled “Supplemental Information Regarding Non-GAAP Financial Measures” in the exhibit to the Company’s most recent Current Report on Form 8-K furnished under Item 2.02. 12
Slide 13: AmerisourceBergen: Where knowledge, reach and partnership shape healthcare delivery
N) AmerisourceBergen*: Where knowledge, reach and partnership shape healthcare delivery.